<DOC>
	<DOCNO>NCT02192970</DOCNO>
	<brief_summary>The investigator hypothesize bevacizumab instill vitreous primary retinal detachment surgery reduce formation proliferative vitreoretinopathy subsequent retinal re-detachment .</brief_summary>
	<brief_title>Bevacizumab Against Recurrent Retinal Detachment</brief_title>
	<detailed_description />
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Vitreoretinopathy , Proliferative</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age â‰¥ 18 year Eyes rhegmatogenous retinal detachment Presence PVR Need procedure primary PPV scleral buckle without PPV , laser retinopexy , pneumatic retinopexy . Recent intravitreal injection antiVEGF agent le 3 month prior Secondary retinal detachment repair Use silicone oil tamponade agent Patients le 18 year age Pregnancy Known allergy contraindication intravitreal bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Retinal detachment</keyword>
	<keyword>Proliferative vitreoretinopathy</keyword>
</DOC>